Celgene (CELG) Offering Possible 25.63% Return Over the Next 6 Calendar Days

Celgene’s most recent trend suggests a bearish bias. One trading opportunity on Celgene is a Bear Call Spread using a strike $86.50 short call and a strike $91.50 long call offers a potential 25.63% return on risk over the next 6 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $86.50 by expiration. The full premium credit of $1.02 would be kept by the premium seller. The risk of $3.98 would be incurred if the stock rose above the $91.50 long call strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Celgene is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Celgene is bearish.

The RSI indicator is at 36.54 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Celgene

NanoString Technologies Inc (NSTG) Q4 2018 Earnings Conference Call Transcript
Fri, 08 Mar 2019 03:20:16 +0000
NSTG earnings call for the period ending December 31, 2018.

I Like the Long Side of Bristol-Myers Squibb
Thu, 07 Mar 2019 16:58:00 +0000
In his second “Executive Decision” segment during Wednesday night’s Mad Money program, Jim Cramer sat down with Giovanni Caforio, chairman and CEO at Bristol-Myers Squibb Co. With the line close to its 2015 highs this speaks more of accumulation (buying) than distribution (selling).

Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4
Thu, 07 Mar 2019 14:06:02 +0000
Merrimack’s (MACK) loss betters estimates in Q4. However, the company fails to earn any revenues in the period.

Top Ranked Value Stocks to Buy for March 7th
Thu, 07 Mar 2019 12:56:12 +0000
Top Ranked Value Stocks to Buy for March 7th

Bristol-Myers CEO: Celgene merger will yield 6 products in 24 months
Thu, 07 Mar 2019 01:22:04 +0000
Jim Cramer interviews Bristol-Myers Squibb CEO Giovanni Caforio to learn about the company’s $74 billion bid for Celgene.

Be Sociable, Share!

Related Posts